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Introduction
Late onset Alzheimer’s disease (LOAD) is an insidious 
neurodegenerative disease responsible for most cases of dementia 
in the elderly. Despite being widely studied, the disease still lacks a 
clear pathogenesis. However, there is a strong genetic component to 
LOAD with 21 disease-risk genetic regions having been identified 
through genome wide association studies (GWAS) [1]. Due to the 
nature of GWAS experimental design, the variants associated through 
GWAS are frequently not the causal functional variants generating 
the disease association. Instead, one or several variants in linkage 
disequilibrium (LD) with the GWAS variant are likely to be causal 
[2,3]. Therefore, due to the large number of the possible causative 
functional variants within these loci, the mechanistic role that each 
of the identified 21 disease-risk genes may play in the progression of 
LOAD remains unknown.
To identify the disease-causing functional variant(s), a number of 
next-generation sequencing (NGS) studies have been undertaken for 
the LOAD GWAS loci. Examples include CLU [4], CLU, PICALM and 
CR1 [5], ABCA7 [6] and ABCA7, BIN1, CD2AP, CLU, CR1, EPHA1, 
MS4A4/MS4A6A [7]. All studies, apart from [5], have used targeted 
exome sequencing, ignoring variants which may be found in the 
noncoding and intronic regions of the loci. Exome sequencing may also 
miss exonic variants which are found close to exon/intron borders [8]. 
Therefore these studies may have overlooked mutations which could 
affect splicing through disrupting donor and acceptor splice sites.
Splicing plays an important role in human genetic disease. Almost 
a third of currently known disease-causing variants disrupt splicing, 
although this is likely to be an underestimate [9,10]. Aberrant splicing 
is implicated in many neurodegenerative disorders [11] and in LOAD, 
variants causing dysfunctional splicing have been found in some of the 
risk genes including PICALM and CD33 [12-14]. 
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 Abstract
Late onset Alzheimer’s disease (LOAD), the most common cause of late onset dementia, has a strong genetic 
component. To date, 21 disease-risk loci have been identified through genome wide association studies (GWAS). 
However, the causative functional variant(s) within these loci are yet to be discovered. This study aimed to identify 
potential functional splicing mutations in the nine original GWAS-risk genes: CLU, PICALM, CR1, ABCA7, BIN1, the 
MS4A locus, CD2AP, EPHA1 and CD33. Target enriched next generation sequencing (NGS) was used to resequence 
the entire genetic region for each of these GWAS-risk loci in 96 LOAD patients and in silico databases were used 
to annotate the variants for functionality. Predicted splicing variants were further functionally characterised using 
splicing prediction software and minigene splicing assays. Following in silico annotation, 21 variants were predicted 
to influence splicing and, upon further annotation, four of these were examined utilising the in vitro minigene assay. 
Two variants, rs881768 A>G in ABCA7 and a novel variant 11: 60179827 T>G in MS4A6A were shown, in these 
cell assays, to affect the splicing of these genes. The method employed in the paper successfully identified potential 
splicing variants in GWAS-risk genes. Further investigation will be needed to understand the full effect of these 
variants on LOAD risk. However, these results suggest a possible pipeline in order to identify putative functional 
variants as a result of NGS in disease-associated loci although improvements are needed within the current 
prediction programme in order to reduce the number of false positives.
Citation: Clement N, Braae A, Turton J, Lord J, Guetta-Baranes T, et al. (2016) Investigating Splicing Variants Uncovered by Next-Generation 
Sequencing the Alzheimer’s Disease Candidate Genes, CLU, PICALM, CR1, ABCA7, BIN1, the MS4A Locus, CD2AP, EPHA1 and CD33. 
J Alzheimers Dis Parkinsonism 6: 276. doi: 10.4172/2161-0460.1000276
Page 2 of 7
Volume 6   Issue 6 • 1000276J Alzheimers Dis Parkinsonism, an open access journal
ISSN:2161-0460
The aim of this study was to discover potentially functional causative 
splicing variants in the original nine genes highlighted through GWAS 
in 2009: CLU, PICALM [15], CR1 [16], ABCA7, BIN1, the MS4A locus, 
CD2AP, EPHA1 and CD33 [17]. Target enrichment and next generation 
sequencing (NGS) were used to sequence the entire GWAS locus for 
each gene as identified through linkage disequilibrium. Coding and 
non-coding variants were prioritised for causality using functional 
annotation. Many of the variants were located close to intron/exon 
boundaries, suggesting a possible role in splicing. These variants were 
taken forward for further in silico investigation and experimental 
assessment of functionality.
Methods 
NGS
Informed consent was obtained from all participants and the 
local Ethics Committee approved the study. 96 CERAD post-mortem 
confirmed LOAD brain tissue samples were obtained from the 
University of Nottingham Brain Bank (n=50) and the Manchester Brain 
Bank (n=46). This sample size gave 80% power to detect variants with a 
minor allele frequency (MAF) as low as 0.85% at a particular location. 
All samples were Caucasian, 52.8% female, with average age at onset of 
70.8 years and APOE alleles: ε2-9.1%; ε3-57.2%; ε4-33.7%, data taken 
when consent obtained or upon receipt of the biological samples. DNA 
was extracted using phenol chloroform, quantified using Quant-iTTM 
ds DNA Broad Range Assay kit (Invitrogen) and combined into eight 
equimolar pools of 12 for a total concentration of 6 ug per pool (500 ng 
per sample). 
Agilent SureSelect Custom MP3 kit designed on eArray with 
5X tiling was used for target enrichment of LOAD associated genes 
including introns, exons and flanking conserved sequence. For ABCA7, 
BIN1, CD33, CR1, CD2AP, EPHA1 and the MS4A locus, repetitive 
elements were masked in SureSelect bait design and the enriched 
library was sequenced by Source BioScience using 100 bp paired-end 
sequencing on the Illumina HiSeq 2000 and base called with Illumina 
Casava 1.9. SureSelect baits for PICALM and CLU were not repeat 
masked and were sequenced separately on the Illumina GAIIx with 38 
bp single-end reads separately. Genomic regions potentially captured 
by these baiting strategies, as well as the transcript IDs for each of the 
genes used, are shown in (Table 1).
Raw data was quality control (QC) checked by FastQC prior to 
alignment to hg19 with BFAST v0.7.0a [18], following the program’s 
protocol for the read type. Aligned files were manipulated using 
SAMtools v0.1.18 [19] and the success of the alignment was assessed 
with SAMtools flagstat function and SAMstat [20]. Variants were called 
using the pooled data specific program, CRISP [21]. Called variants 
were filtered following the best practice variant detection suggested 
by Genome Analysis ToolKit pipeline (GATK v4.0, Broad Institute 
[22]. Variants were annotated using Ensembl’s Variant Effect Predictor 
(VEP) [23] supplemented with annotations from Encyclopaedia 
of DNA Elements (ENCODE) project and PhastCons downloaded 
from the UCSC genome browser website (http://genome.ucsc.edu/
ENCODE/downloads.html, accessed Nov 2012 [24]) using a custom 
in-house script. 21 variants identified as potentially affecting splicing 
(falling within 1-3 bp of exon and 1-12 bp of intron) were carried 
forward for further investigation. Given the difficulties identifying 
intronic mutations which affect branch point sites and the large number 
of intronic variants called, these were not taken forward in this project. 
Linkage disequilibrium (LD) between the variants of interest and the 
GWAS variants were calculated with VCFtools [25] using 1000Genomes 
Phase 1 data for samples of northern European Ancestry [26]. 
In silico analysis of splicing
Additional in silico programs were used to assess the 21 identified 
splicing SNPs. Namely, ESEfinder v3 (http://rulai.cshl.edu/cgi-bin/
tools/ESE3/esefinder.cgi?process=home) [27], Berkley Drosophila 
Genome Project Splice Site Prediction by Neural Network (BDGP) 
(http://www.fruitfly.org/seq_tools/splice.html) [28] and Human 
Splicing Finder (HSF) (http://www.umd.be/HSF3/) [29]. All programs 
were accessed March 2015.
Four potential variants were taken forward that showed differences 
between the two alleles in all three programs, including a score change 
of more than 10% between the major and the alternative allele where 
numerical scores were provided. 
In vitro analysis of splicing
As additional brain tissue was not available for all samples in order 
to perform RNA extractions, as well as the previous DNA extractions 
already performed, the minigene assay was selected to validate potential 
splicing variants. This method has been shown to have 
complete concordance with RT-PCR analysis of patient RNA and is 
a validated and reliable method for investigating splicing [30]. 
All methods were performed following manufacturer’s protocol 
unless otherwise specified. The specific sample in each pool containing 
the heterozygous splice variant was identified by Sanger sequencing the 
appropriate exon(s) in each locus. 
Minigene primers with the addition of SalI and XbaI restriction 
enzyme binding sites were designed using the relevant ABCA7, 
MS4A6A and EPHA1 reference sequences using Primer 3 (v.0.4.0) 
Gene Transcript  ID Chromosome Coordinates BP
CLU NM_001831.3 8 27 450 849-27 475 277 24,430
PICALM NM_007166.3 11 85 665 237-85 783 519 118,280
CR1 NM_000651 1 207 667 495-207 816 719 149,224
ABCA7 NM_019112 19 1 038 952–1 066 720 27,768
BIN1 NM_139343.2 2 127 778 085–127 895 723 117,638
MS4A LD Locus
NG_016014 
NM_152852 
XM_005274415
11 59 856 028–60 041 296 185,268
CD2AP NM_012120 6 47 427 281–47 601 015 173,734
EPHA1 NM_005232 7 143 082 382-143 110 385 28,003
CD33 NM_001772 19 51 718 317-51 748 546 30,229
Table 1: Regions of the genome (chromosome number and coordinates) to be targeted by Agilent SureSelect baits for the sequencing project. 
Coordinates are given relative to hg19. BP refers to how many bases can potentially be covered by the design. The Ensembl transcript IDs presented were utilised in all 
analysis of the sequence data as well as annotation of variants 
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(http://frodo.wi.mit.edu/primer3/). Amplicons were designed to 
contain the potential splicing mutations, adjacent exons and intronic 
sequences (Supplementary Table 1). 
Initial PCR was carried out using 10-100 ng template DNA in 
30μl reaction volumes with Expand High Fidelity Taq (Roche). PCR 
conditions for all reactions were as follows: an initial denaturing step of 
2 min at 94°C, followed by 30 cycles of 15 s at 94°C, 30 s at optimized 
annealing temperature (Ta, Supplementary Table 1) and 40 s, plus 5 s 
every cycle, at 72°C with a final extension step at 72°C for 7 min.
Amplicons were cloned into pCR 2.1-TOPO vectors using the 
TOPO TA Cloning kit (Invitrogen, Life Technologies) before being 
ligated into the exon trap vector, pET01 (MoBiTech) and transformed 
into NEB High Efficiency 5-alpha chemically competent E. coli cells 
C2987I. Vector DNA was then extracted following the NucleoBond 
Xtra Midi Plus EF Kit in an endotoxin free environment as well as being 
sequenced to confirm the insert sequence was accurately cloned.
Two cell lines were obtained from the European Collection of Cell 
Cultures (ECCC): CV-1 in Origin, carrying SV40 (COS-7) derived 
from monkey African green kidney cells and human Caucasian 
neuroblastoma cells (BE(2)-C). COS-7 is typically used for testing 
minigene splicing assays as it is easy to transfect and grow, as well as 
being known to accurately represent the complex eukaryotic splicing 
environment seen in vivo. BE(2)-C cells were selected in order to 
investigate possible neurological-specific splicing effects due to the 
brain’s unique spliceosome. COS-7 were cultured in Dulbecco’s 
Modified Eagle Medium (DMEM) with 10% Foetal Bovine Serum 
(FBS), 2 mM L-Glutamine, 100 U/ml penicillin-streptomycin and 100 
U/ml fungizone and BE(2)-C were cultured in 1:1 Eagle’s Minimal 
Essential Medium (EMEM):Ham’s F12 with 1% non-essential amino 
acids, 2 mM Glutamine, 15% FBS, 100 U/ml penicillin-streptomycin 
and 100 U/ml fungizone. The COS-7 and BE(2) cells were plated out 
at 3.5 × 105 cells per plate and 6 × 105 cells per plate, respectively. Cells 
were transfected using TransFact (Promega) and incubated for 24 
h. The transfection was repeated in triplicate in each cell line. Total 
RNA was then extracted utilising the RNeasy Mini Kit (Qiagen) with 
the additional on column DNase treatment (TURBO DNA-free Kit, 
Ambion). Total cDNA was synthesised with AffinityScript Multiple 
Temperature cDNA Synthesis kit (Agilent) using oligodT primers. The 
cDNA of interest was then PCR amplified in a 30 µl reaction volume 
using LongAmp Taq (New England BioLabs) and primers specific to 
the pET01 vector (Forward: GATCGATCCGCTTCCTG, Reverse: 
CACTGGAGGTGGCCCG). The thermal cycling conditions were: 30 s 
at 94°C for initial denaturation, followed by 30 cycles of 15 s at 94°C for 
denaturation, 30 s at 59°C for annealing and 50 s at 65°C for extension 
and 10 m at 65°C for the final extension. Amplicons were compared 
by electrophoresis as well as Sanger sequenced in order to undertake a 
more detailed comparison.
Results 
NGS study
An average of 245.5 million reads per pool was obtained. The eight 
pools of twelve passed all FastQC parameters apart from sequence 
duplication which is to be expected given the sequencing strategy 
employed.
The flagstat analysis in SAMtools showed that 99% of reads were 
mapped correctly and 95-99% of reads were properly paired. CRISP 
called 3205 variants within the nine loci, with 760 novel variants. 
The minor allele frequency estimates from CRISP were strongly 
positively correlated with frequencies found in the 1000 Genomes 
project indicating successful variant calling (Spearman Correlation 
Coefficient=0.60, p<0.0001 across all gene regions examined). 
Following annotation, only 126 exonic variants were called with the 
majority of variants being non-coding. There were 43 variants in 
untranslated regions (UTRs) and 44 missense variants (Supplementary 
Table 2). As defined above, 21 variants were predicted to affect splicing 
(Supplementary Table 2).
In silico analysis of splicing
All 21 variants were further annotated by three in silico programs, 
the results of which can be seen in (Supplementary Table 3). From 
this original list of 21 variants, four were predicted to be splice site 
variants by at least two programs by altering the donor or acceptor sites 
(predicted by the BDGP and HSF programs) as well as altering splicing 
factor binding sites (predicted by ESEfinder) (Table 2). These variants 
(19:1054696 and rs881768 in ABCA7, 11:60179827 in MS4A6A and 
rs6967117 in EPHA1) were therefore analysed in vitro in order to assess 
the accuracy of these predictions. 
In vitro analysis of splicing
For two of the variants analysed (19:1054696 in ABCA7 and 
rs6967117 in EPHA1) there was no difference between the RNA 
extracted from cells transfected with the wild-type insert and the 
mutant insert in both BE(2)-C and COS-7 cell lines. This was apparent 
on both gel electrophoresis and sequencing of the RT-PCR products.
The ABCA7 variant rs881768 A>G, however, produced different 
results between the wild-type and mutant constructs upon analysis 
of RT-PCR products, as shown in (Figure 1). The major product with 
both constructs (when either the A or G allele was present) had exon 
32 spliced out, leaving only vector sequence. With the mutant construct 
there was also a minor product, where exon 32 was included, suggesting 
low levels of exon 32 inclusion with the minor allele haplotype. This was 
evident in both COS-7 and BE(2)-C cell lines. 
The MS4A6A variant at genomic position 11: 60179827 T>G also 
showed some differences between constructs, presented in (Figure 2). 
The major product with the wild-type construct, as predicted, contained 
both the vector exons and exon 4 of the gene. There was also a minor 
product present which contained just the vector sequence, suggesting 
low levels of a gene product with this exon spliced out. The only product 
with the mutant construct showed exon 4 spliced out. These results 
were obtained with both COS-7 and BE(2)-C cells lines. 
Discussion 
A 2013 GWAS meta-analysis for LOAD used over 74000 samples 
to identify 11 new disease-risk genes and confirmed 10 previous 
susceptibility loci (CLU, PICALM, CR1, BIN1, ABCA7, the MS4A locus, 
CD2AP, EPHA1, the HLA-DRB5-HLA-DRB1 locus, PTK2B, SORL1, 
SLC24A4-RIN3, INPP5D, MEF2C, NME8, ZCWPW1, CELF1, FERMT2 
and CASS4 [1]). The population attributable risk for each of these loci 
range from 1 to 8% indicating further genetic risk factors remain to be 
discovered for LOAD [1].
This study used targeted sequencing to identify 21 potential 
splicing variants located in nine of the original genetic loci associated 
with LOAD in 96 patients. Following the in silico assessment of the 
variants’ impact on splicing, four variants were put forward for in 
vitro confirmation using hybrid minigenes in the pET01 vector. Only 
two of the variants were confirmed to be functional; rs881768 A>G in 
ABCA7 and novel variant 11: 60179827 T>G in MS4A6A, part of the 
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MS4A locus. This suggests that the methods currently used to prioritize 
potential functional variants need further refinement.
The synonymous variant rs881768 is located at the first base of 
exon 32 in ABCA7 (transcript ID NM_019112) and is in linkage 
disquilibrium with the ABCA7 GWAS variant (D’=0.824, Table 2). In 
silico predictions suggest that the G allele creates a new donor site with 
a similar score to the original donor site, located only 126 bp away (a 
score of 0.98 compared with 0.99) and changes the binding of two exon 
splicing enhancer (ESE) proteins (Table 2). These predictions suggest 
the G allele could activate a cryptic splice site or cause a change in 
protein isoform ratios. However, population data from 1000 Genomes 
Gene 
(Transcript ID)
Genomic 
Location (rsID)
Transcript 
location Ref/Alt MAF D’ ESEfinder BDGP
Human Splicing 
Finder
Combined predicted 
consequence
ABCA7 
(NM_019112)
19:1054696
(-)
Intron 28-29
 +3 bp G/C 0.010 NA
SRSF2 site 
gained
Known functional donor 
site with a score of 0.91 
reduced to a score of 0.38
Alteration of an 
intronic ESS site.
Change in ESE and intronic 
ESS site could change 
transcript isoform ratio.
19:1056066
(rs881768)
Exon 32
1 bp A/G 0.250 -0.824
SRSF1 site 
gained, 
SRSF6 site 
lost
Novel donor site created 
with a score of 0.98
Strengthens known 
functional acceptor site 
score from 0.56 to 0.76
A cryptic donor site 
is activated.
Activation of donor site at start 
of exon might result in exon 
skipping.
MS4A6A* 
(NM_152852)
11: 60179827
(-)
Intron 4-5
+4 bp T/G 0.480 NA
SRSF5 sites 
lost
Known functional donor 
site with a score of 0.66 
lost
Activation of intronic 
cryptic acceptor site, 
and intronic cryptic 
donor site and 
creation of intronic 
ESE site.
Loss of existing donor site 
could result in exon skipping. 
However, activating intronic 
acceptor or donor site could 
result in a change in the 
sequence included in the exon.
EPHA1* 
(NM_005232)
7:143391774
(rs6967117)
Exon 17 
+1bp T/C 0.060 0.75
SRSF1 site 
gained 
Novel donor site created 
with score of 0.49.
A cryptic donor site 
is activated.
Activation of donor site at start 
of exon might result in exon 
skipping.
Table 2: Prioritised splicing variants from the NGS study selected for further experimental investigation.
Genomic location is relative to GRCh38 and rsID is provided where available, (-) defines no rsID for this genomic location. Genes located on the reverse strand are indicated 
(*) and transcripts of these genes used are provided, defined by Ensembl.org. The reference and alternative allele for the forward strand as called in CRISP are shown 
(Ref/Alt) as is the minor allele frequency (MAF). The Linkage Disequilibrium between the SNP presented and the GWAS tag SNP for that gene is also presented in the D’ 
format. “NA” defines the LD is unavailable, most likely due to the variant in question not being present in the CEU population in the 1000 Genomes database. All variants 
resulted in results indicating they have the potential to alter splicing by all three in silico programmes used (ESEfinder, BDGP and Human Splicing Finder). SRSF = Serine/
arginine-rich splicing factor, ESE=Exonic Splicing Enhancer and ESS=Exonic Splicing Suppressor.
Figure 1: (A) RT-PCR products generated using total RNA extracted from BE(2)-C cells containing both the wild-type (wt) and mutant (mut) constructs for ABCA7 
variant rs881768. (B) Sequence of product generated by the major and minor allele (wt and mut) containing only vector exons. (C) Sequence of mutant construct (mut) 
minor allele product containing exon 32 suggesting low levels of exon 32 inclusion in the presence of the minor allele haplotype.
Citation: Clement N, Braae A, Turton J, Lord J, Guetta-Baranes T, et al. (2016) Investigating Splicing Variants Uncovered by Next-Generation 
Sequencing the Alzheimer’s Disease Candidate Genes, CLU, PICALM, CR1, ABCA7, BIN1, the MS4A Locus, CD2AP, EPHA1 and CD33. 
J Alzheimers Dis Parkinsonism 6: 276. doi: 10.4172/2161-0460.1000276
Page 5 of 7
Volume 6   Issue 6 • 1000276J Alzheimers Dis Parkinsonism, an open access journal
ISSN:2161-0460
shows that the G allele is actually the ancestral allele with a European 
population allele frequency of 0.44. Additionally, score predictions for 
the acceptor site shows that the A allele has a lower score than the G 
allele (0.56 compared to 0.76) which could lead to exon skipping. This 
makes in silico functional prediction of this variant very difficult. 
In the minigene assays the G allele causes low levels of exon 32 
to be incorporated into the transcript, while the A allele causes exon 
32 to be spliced out. Expressed sequence tag (EST) databases such as 
GTEx portal [31] show exon 32 is incorporated in most transcripts and 
utilising this transcript data to examine the effect of rs881768 shows 
that this variant has no effect on splicing in this database. ABCA7 has an 
interesting pattern of alternative splicing, with many introns consisting 
of multiples of three, potentially allowing in-frame addition and 
deletion of introns, although no such transcripts have been identified. 
Exon 32, however, does results in a frame-shift change creating a 
termination codon in the next exon and causing early truncation of 
the protein. This truncated protein is non-functional as it lacks the 
last five transmembrane domains and the second nucleotide binding 
domain and may be targeted for nonsense mediated decay. This would 
prevent any truncated proteins being expressed causing sole expression 
of the complete isoform, explaining the lack of this truncated protein in 
databases such as GTEx.
The novel variant identified in MS4A6A, part of the MS4A locus, 
11:60179827 T>G is found 4 bp into the intron between exon 4 and 5. 
The G allele removes the native donor site for exon 4/intron 4 possibly 
causing exon skipping (Table 2). However, a cryptic donor site is 
activated and the binding of two ESE proteins are affected, potentially 
changing the sequence included in the transcript. The minigene assays 
show that the G allele does appear to cause exon skipping, creating 
transcripts without exon 4. However, the T allele, while mostly 
producing transcripts which contain exon 4, also produces a small 
proportion of transcripts without exon 4. Transcripts without exon 
4 appear to be produced by both alleles despite the removal of exon 
4 generating a truncated protein which lacks two transmembrane 
domains and one noncytoplasmic domain. Although the G allele 
does cause exon 4 to be excluded through obliterating the donor site, 
there must be additional alternative splicing regulation mechanisms 
occurring within the in vitro assay, as well as in vivo, which affect the 
levels of each isoform being produced explaining the presence of both 
isoforms in the presence of the T allele. 
To fully explore the role both of these variants play in splicing, 
direct analysis of RNA samples from affected tissues from LOAD 
individuals with the variants should be examined. Unfortunately for 
rare variants in LOAD this tissue is not always readily available. Epstein-
Barr transformed cell lines used for 1000 Genomes project, however, 
are a possible alternative. Targeted sequencing of RNA extracted 
from these cell lines selected to be homozygous for different alleles 
could be compared to the results of the minigene assays. This would 
determine the role of these splicing variants in an environment where 
the whole genome is present, rather than just the fragment inserted 
in the minigene assay. There is also publicly available RNA-seq data 
from these cell lines (see the GEUVADIS project [32]); unfortunately 
coverage for many of the LOAD risk loci is poor.
While only two variants show aberrant splicing in this study, 
dysfunctional splicing has been previously implicated in LOAD. 
Distinctive patterns of alternative splicing and promoter use were 
discovered in LOAD brain tissue through comparing the transcriptome 
profiles of the frontal, temporal and parietal lobes of AD patients with 
Figure 2: (A) RT-PCR products generated using total RNA extracted from BE(2)-C cells containing both the wild-type (wt) and mutant (mut) constructs for the variant 
at position 11:59947300 in the MS4A6A gene. (B) Sequence of the major product with the wild-type construct (wt) containing exon 4. (C) Sequence with the mutant 
construct (mut) demonstrating exon 4 removed.
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controls [33,34]. Additionally, small nuclear and heterogeneous nuclear 
ribonucleoproteins have been shown to be disrupted in LOAD [35,36]. 
Therefore the role of splicing in LOAD disease pathology should not 
be ignored.
Identifying variants that have a functional role in complex diseases 
is a challenge [37]. This is particularly true for next generation 
sequencing studies which identify large numbers of potential functional 
variants. The problem arises while attempting to prioritise the variants 
for further functional assays or experiments. Current in silico databases 
have minimal experimental information available. The annotation 
programs used need to be chosen carefully in order to correctly assign 
potential functionality and ensure pathogenic variants are found.
Prediction algorithms for exonic and intronic splicing enhancer 
and silencer sites are less robust than programs predicting disruptions 
of 3’ and 5’ consensus splice site regions. This is largely because more 
is known about the 3’ acceptor and 5’ donor consensus sequences, thus 
allowing better prediction models to be built [38]. Due to this, the initial 
selection of splicing variants in this study selected variants within 1-3 bp 
of an exon or 1-12 bp of an intron, biasing the selection towards variants 
that may disrupt consensus splice sites. The BDGP and HSF prediction 
programs used in this study both examine the effects of mutations on 3’ 
(acceptor) and 5’ (donor) consensus sequences. The two variants that 
had an effect on splicing in vitro were both predicted to affect acceptor 
and or donor consensus sites by BDGP and HSF (Table 2).
The recognition of exon and intron borders in pre-mRNA by the 
spliceosome does not simply involve identifying the correct consensus 
3’ and 5’ splicing sequences. A multitude of splicing regulatory 
proteins and ribonucleoproteins interact to precisely control splicing 
and influence the levels of different transcript isoforms created [39]. 
Many variants that disrupt splicing are found deep within exons and 
introns and affect splicing through the disruption of exonic or intronic 
splicing enhancers or silencers [40]. Through limiting the analysis 
to variants located near consensus splice sites, as in this study, these 
mutations will be missed. With the advent of additional functional 
experimental studies, predictions of mutations influencing the binding 
of RNA proteins can only improve and would be useful for future 
work. This issue has recently been addressed by ANNOVAR, with the 
option to include bulk annotations from the SPIDEX dataset. This 
dataset provides an improved algorithm for detecting potential splicing 
variants [41]. However, a review of the method suggests that two 
other prediction methods for exonic splicing regulatory elements may 
perform better [42]. 
Conclusion
Pooled NGS with target enrichment successfully identified potential 
functional splicing variants in nine gene regions associated with 
LOAD. Through targeting the entire genomic sequence, we were able to 
investigate variants in these regions which potentially affect consensus 
splice sites in silico and in vitro. Improvements are needed in current 
splicing prediction programs to reduce the number of false positives 
which are taken forward for analysis as well as reducing the number of 
false negatives discarded prior to further investigation. Further work is 
needed to fully clarify the role that the variants rs881768 (ABCA7) and 
11: 60179827 T>G (MS4A6A) may have in LOAD in vivo.
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